PointState Capital’s PTC Therapeutics PTCT Stock Holding History

PointState Capital’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-324,000	Closed	-$10.9M	–	175
2018 Q2	$10.9M	Buy	+324,000	New	+$10.1M	0.12%	98
2015 Q4	–	Sell	-150,000	Closed	-$4M	–	105
2015 Q3	$4M	Sell	150,000 -125,000	-45%	-$5.35M	0.11%	70
2015 Q2	$13.2M	Buy	+275,000	New	+$16M	0.15%	83

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

PointState Capital's PTCT Position: Q3 2018 in Review

PointState Capital sold out of PTC Therapeutics (PTCT) in Q3 2018, closing a stake of 324,000 shares — an estimated $10.9M sold.

PointState Capital first reported a position in PTCT in Q2 2015 and held it in 3 quarters. The position peaked at $13.2M in Q2 2015. 180 funds tracked by Wall St. Rank hold PTCT as of Q3 2018.

PointState Capital reported no remaining PTC Therapeutics position as of Q3 2018 after selling out during the quarter.
PointState Capital sold 324,000 PTC Therapeutics shares in Q3 2018, an estimated $10.9M.
PointState Capital first reported a position in PTC Therapeutics in Q2 2015 and held it in 3 quarters.
PointState Capital's PTC Therapeutics position peaked at $13.2M in Q2 2015.
180 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2018.

Based on PointState Capital's 13F filing for Q3 2018, filed 14 Nov 2018.